MA5-14509

antibody from Invitrogen Antibodies

Targeting: ERBB2 CD340, HER-2, HER2, NEU, NGL

Antibody data

Submit

Validation data

Product number: MA5-14509 - Provider product page
Provider: Invitrogen Antibodies
Product name: ErbB2 (HER-2) Recombinant Rabbit Monoclonal Antibody (SP3)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: MA5-14509 targets HER-2 in IHC (P) applications and shows reactivity with Human samples. The MA5-14509 immunogen is recombinant protein encoding extracellular domain of human HER-2.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Antibody clone number: SP3
Vial size: 500 µL
Concentration: 0.122 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

ERBB2 protein structure - MA5-14509 shown in red.

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 In vitro evaluation of Her2 expression and ADC cytotoxicity. The expression of Her2 and the in vitro cytotoxicity of the ADCs are evaluated in the HCC-1954, NCI-N87, MDA-MB-453 and MDA-MB-468 cell lines. (A) The cell surface expression of Her2 is measured via FACS for a panel of tumor cell lines. HCC-1954, MDA-MB-453 and NCI-N87 were selected as the Her2 expressing cell lines while MDA-MB-468 was selected as the Her2 negative cell line. MDA-MB-453 cells are resistant to Herceptin. (B) NCI-N87 and HCC-1954 tumor xenografts were evaluated for Her2 expression via IHC. (C) The in vitro cytotoxicity of the anti-Her2 ADCs were evaluated in the HCC-1954, NCI-N87, MDA-MB-453 and MDA-MB-468 cell lines.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Posterior whole-body coronal microSPECT/CT images of a NRG mouse bearing s.c. implanted HNSCC PDX at a. 6 h, b. 24 h or c. 48 h p.i. of [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 or d. 24 h p.i. of irrelevant [ 177 Lu]Lu-DOTA-trastuzumab F(ab') 2 . The tumour is shown by the white arrow. At 6 h p.i., the mediastinum (blood pool; white arrowhead), liver (blue arrowhead) and kidneys (broken white circles) were visualized, while at 24 and 48 h p.i., the liver and kidneys were the main normal organs visualized. e. Immunohistochemical staining of the excised tumour demonstrated very low HER2 expression

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Conducting 3D-FISH validations of the PRKD3 loop in organoids of BC tissues. A Images of organoids derived from normal breast tissue (NT), primary breast cancer tissue (PT) and tamoxifen-treated breast cancer recurrent tissue (RT). Scale bar at 50 um. B IHC staining of ER and PR in organoids of NT, PT and RT respectively with a higher magnification (40X) and a scale bar at 50 um. C Western blotting showing ER, PR, HER2 and Ki67 protein levels in organoids of NT, PT and RT, respectively. beta-actin levels were measured as a loading control. D 3D-FISH images showing interaction frequency of the PRKD3 loop in organoids of PT and RT, respectively. BAC probe combinations: promoter (green) and distal region (red) n = 50, DAPI DNA stain (blue). Square boxes in red represent the magnified view of each interaction. Scale bar at 5 um. E Distributions of measured distances of the PRKD3 loop are significantly different for PT vs. RT (* p